Einzeltreffer — DigiBib

HPV vaccination with concomitant HPV-based screening of young women has been proposed for faster cervical cancer elimination. We describe the baseline results of a population-based trial of this strategy to reduce the incidence of HPV. All 89,547 women born 1994-1999 and resident in the capital region of Sweden were personally invited to concomitant HPV vaccination and HPV screening with 26,125 women (29.2%) enrolled between 2021-05-03 and 2022-12-31. Baseline HPV genotyping of cervical samples from the study participants finds, compared to pre-vaccination prevalences, a strong decline of HPV16 and 18 in birth cohorts previously offered vaccination, some decline for cross-protected HPV types but no decline for HPV types not targeted by vaccines. Our dynamic transmission modelling predicts that the trial could reduce the incidence of high-risk HPV infections among the 1994-1998 cohorts by 62-64% in 3 years. Baseline results are prevalences of HPV infection, validated transmission model projections, and power estimates for evaluating HPV incidence reductions at follow-up (+/-0.1% with 99.9% confidence). In conclusion, concomitant HPV vaccination and HPV screening appears to be a realistic option for faster cervical cancer elimination. Clinicaltrials.gov identifier: NCT04910802; EudraCT number: 2020-001169-34.

Titel:	Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.
Autor/in / Beteiligte Person:	Arroyo Mühr, LS ; Gini, A ; Yilmaz, E ; Hassan, SS ; Lagheden, C ; Hultin, E ; Garcia Serrano, A ; Ure, AE ; Andersson, H ; Merino, R ; Elfström, KM ; Baussano, I ; Dillner, J
Link:	View record at Springer (Volltext)
Zeitschrift:	Nature communications, Jg. 15 (2024-05-01), Heft 1, S. 3679
Veröffentlichung:	[London] : Nature Pub. Group, 2024
Medientyp:	academicJournal
ISSN:	2041-1723 (electronic)
DOI:	10.1038/s41467-024-47909-x
Schlagwort:	Humans Female Adult Sweden epidemiology Young Adult Vaccination Adolescent Incidence Mass Screening Prevalence Middle Aged Early Detection of Cancer Human papillomavirus 16 genetics Human papillomavirus 16 immunology Human papillomavirus 18 genetics Human papillomavirus 18 immunology Human Papillomavirus Viruses Uterine Cervical Neoplasms prevention & control Uterine Cervical Neoplasms virology Uterine Cervical Neoplasms epidemiology Papillomavirus Infections epidemiology Papillomavirus Infections prevention & control Papillomavirus Infections virology Papillomavirus Vaccines immunology Papillomavirus Vaccines administration & dosage Papillomavirus Vaccines therapeutic use
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Nat Commun] 2024 May 01; Vol. 15 (1), pp. 3679. <i>Date of Electronic Publication: </i>2024 May 01. MeSH Terms: Uterine Cervical Neoplasms* / prevention & control ; Uterine Cervical Neoplasms* / virology ; Uterine Cervical Neoplasms* / epidemiology ; Papillomavirus Infections* / epidemiology ; Papillomavirus Infections* / prevention & control ; Papillomavirus Infections* / virology ; Papillomavirus Vaccines* / immunology ; Papillomavirus Vaccines* / administration & dosage ; Papillomavirus Vaccines* / therapeutic use ; Humans ; Female ; Adult ; Sweden / epidemiology ; Young Adult ; Vaccination ; Adolescent ; Incidence ; Mass Screening ; Prevalence ; Middle Aged ; Early Detection of Cancer ; Human papillomavirus 16 / genetics ; Human papillomavirus 16 / immunology ; Human papillomavirus 18 / genetics ; Human papillomavirus 18 / immunology ; Human Papillomavirus Viruses References: Expert Rev Vaccines. 2019 Feb;18(2):153-160. (PMID: 30657348) ; Br J Cancer. 2011 Jun 28;105(1):28-37. (PMID: 21629249) ; Int J Gynecol Cancer. 2020 Apr;30(4):426-427. (PMID: 32122950) ; Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):242-50. (PMID: 23221127) ; Salud Publica Mex. 2018 Nov-Dic;60(6):612-616. (PMID: 30699264) ; Theor Biol Med Model. 2008 Feb 27;5:4. (PMID: 18304361) ; Vaccine. 2010 Jul 26;28(33):5473-84. (PMID: 20573580) ; Vaccine. 2020 Feb 5;38(6):1345-1351. (PMID: 31917039) ; EClinicalMedicine. 2022 Feb 19;45:101306. (PMID: 35243272) ; J Infect Dis. 2016 Jan 15;213(2):199-205. (PMID: 26142436) ; Lancet. 2014 Dec 20;384(9961):2213-27. (PMID: 25189358) ; Prev Med. 2019 Mar;120:26-33. (PMID: 30593796) ; Lancet Public Health. 2016 Nov;1(1):e8-e17. (PMID: 29253379) ; PLoS One. 2013 Nov 29;8(11):e81171. (PMID: 24400036) ; J Clin Virol. 2022 Sep;154:105237. (PMID: 35820294) ; Nat Rev Clin Oncol. 2016 Feb;13(2):119-32. (PMID: 26323382) ; PLoS Med. 2023 Oct 27;20(10):e1004304. (PMID: 37889928) ; Prev Med. 2021 Dec;153:106827. (PMID: 34599922) Grant Information: 201199UsF02H Cancerfonden (Swedish Cancer Society); 201198PjF01H Cancerfonden (Swedish Cancer Society); 2021-01228 Vetenskapsrådet (Swedish Research Council); 847845 EC \| Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) Molecular Sequence: ClinicalTrials.gov NCT04910802 Substance Nomenclature: 0 (Papillomavirus Vaccines) Entry Date(s): Date Created: 20240501 Date Completed: 20240501 Latest Revision: 20240513 Update Code: 20240514 PubMed Central ID: PMC11063066

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.